Close Menu
    Trending
    • IGEL Reaches Unicorn Status with Strategic Investment from Vitruvian Partners to Accelerate Growth of its Endpoint Security and Cyber Resilience Endpoint Platform for Enterprise
    • Booking Holdings Unveils Booking Partner Division to Accelerate B2B Travel Innovation
    • Ebola adds 60 cases in a day as Congo deaths hit 5,568
    • Dubai Airports expects over 70 million guests in 2026
    • Rand slips toward R17 as inflation and weak growth cloud outlook
    • Sinopec Co-Hosts Final of Youth Cultural Ambassador Competition in Algiers
    • Sokin expands in the UAE with DFSA license, local AED payment rails and accounts
    • Tencent Cloud Powers HooLive to Deliver Enhanced Digital Entertainment Experiences in Saudi Arabia
    • Home
    • Contact Us
    Irani TimesIrani Times
    Wednesday, November 18
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Irani TimesIrani Times
    Home » PromiCell, Inc. presents during JP Morgan’s 2026 Healthcare Conference
    ACCESS Newswire

    PromiCell, Inc. presents during JP Morgan’s 2026 Healthcare Conference

    January 10, 2026
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the “Company”), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company’s Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company’s lead asset PRO CAR – 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level).

    About PromiCell, Inc.

    PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 TCR T cells and CD 33 CAR T cells, applicable for the treatment of patients with mCRPC, Ewing Sarcoma, recurrent leukemia and acute myeloid leukemia. Our next-generation chimeric antigen receptor CAR T cell therapies are designed to address key mechanisms of tumor escape, disease relapse, and immune evasion. Our scientists are pioneers in CAR T-cell therapy, united in a mission to outsmart cancer and deliver more cures for patients. Learn more at www.promicell.com.

    Contact:

    305-433-1287
    anthony@promicell.com

    SOURCE: Promicell

    View the original press release on ACCESS Newswire

    Related Posts

    Chevron Signs 3-Year Agreement with UptimeAI, Scaling Expertise to Enhance Asset Reliability and Operational Efficiency

    November 17, 2026

    Pitches and Keynote Speakers Are Confirmed for Blue Magic Netherlands on November 17

    November 4, 2026

    Chervon Names Jody Grimsley Senior National Account Manager

    November 2, 2026

    GA-ASI and Saab Perform Advanced AEW Flight Testing on Uncrewed MQ-9B

    October 28, 2026

    Chervon Names Parker Wesley Clary Director of Field Sales – Southern Division

    October 26, 2026

    Study Finds Lower Rates of Overweight Among Vegan-Fed Cats

    October 23, 2026
    Latest News

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    Dubai Airports expects over 70 million guests in 2026

    November 18, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    Over 9 million visitors lift Tunisia tourism income 3.4%

    November 17, 2026
    © 2026 Irani Times | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.